Chile Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Chile Pharmaceuticals and Healthcare Report Q3 2013 Jul 10th 2013, 00:00, by rnrmahesh BMI View: The lack of vigilance in bioequivalence regulations in Chile has allowed for the proliferation of low quality medicines in the market. These can risk patients’ lives and negatively affect the local pharmaceutical industry’s global competitiveness. Despite the ongoing capacity issues reported by domestic manufacturers, we believe generic drugmakers in Chile need to adopt necessary production processes to guarantee their drug quality. Headline Expenditure Projections ? Pharmaceuticals: CLP1,603bn (US$3.3bn) in 2012 to CLP1,715bn (US$3.6bn) in 2013; +7.0% in local currency terms and +8.9% in US dollar terms. ? Healthcare: CLP9,825bn (US$20.2bn) in 2012 to CLP10,629bn (US$22.3bn) in 2013; +8.2% … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=105996. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/chile-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions